Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia

INTRODUCTION: Naftopidil, approved initially in Japan, is an α1d-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is different from tamsulosin hydrochloride and silodosin, in that it has a higher affinity for...

Descripción completa

Detalles Bibliográficos
Autores principales: Griwan, Mahavir Singh, Karthikeyan, Y. R., Kumar, Mandeep, Singh, Bikram Jit, Singh, Santosh Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127851/
https://www.ncbi.nlm.nih.gov/pubmed/25125888
http://dx.doi.org/10.4103/0974-7796.134254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127851/
https://www.ncbi.nlm.nih.gov/pubmed/25125888
http://dx.doi.org/10.4103/0974-7796.134254

Ejemplares similares